borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
(a)
As of December 31, 2024, our investment in Haleon is reported in
Short-term investments
and as of December 31, 2023 was reported in
Equity-method investments
. See
Note 2C
. Short term equity securities as of December 31, 2024 include and as of December 31, 2023 represent money market funds primarily invested in U.S. Treasury and government debt.
(b)
Represent investments in the life sciences sector.
Debt Securities
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
(a)
Reported in
Other (income)/deductions
––
net
. See
Note 4
.
(b)
Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2024, there were cumulative impairments and downward adjustments of $
360
million and upward adjustments of $
222
million. Impairments, downward and upward adjustments were not material to our operations in 2024, 2023 and 2022
.
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
C. Short-Term Borrowings
(a)
Issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen (see
Note 2A
). The weighted-average effective interest rate on commercial paper outstanding was approximately
4.94
%
as of December 31, 2024 and
5.37
% as of December 31, 2023.
(b)
Primarily includes cash collateral. See
Note 7F
.
As of December 31, 2024, we had access to a total of $
15
billion in committed U.S. revolving credit facilities, consisting of an $
8
billion facility maturing in October 2025 (subsequently terminated by Pfizer in February 2025), and a $
7
billion facility maturing in October 2029, which may be used for general corporate purposes including to support our global commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional $
276
million in lines of credit, of which $
243
million expire within one year. Essentially all lines of credit were unused as of December 31, 2024.
D. Long-Term Debt
(a)
Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.
(b)
Reclassified to the current portion of long-term debt.
Issuance—
In May 2023, we issued, through our wholly-owned finance subsidiary, PIE, $
31
billion principal amount of senior unsecured notes at an effective interest rate of
4.93
% as part of the financing for our acquisition of Seagen. The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the acquisition of Seagen and has